Status:
UNKNOWN
18F-FAPI PET in the Diagnosis of Liver Fibrosis
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Conditions:
Liver Fibrosis
FAP
Eligibility:
All Genders
18-85 years
Brief Summary
It is an open label observation clinical trial, all participants are chronic liver disease. The investigators deem to make a novel evaluate criteria to hepatic fibrosis. The point of the clinical tria...
Detailed Description
Participants are with clinically confirmed chronic liver disease,including chronic viral hepatitis, autoimmune hepatitis, liver disease after liver transplantation, nonalcoholic fatty liver disease, a...
Eligibility Criteria
Inclusion
- Clinically confirmed chronic liver disease,including chronic viral hepatitis, autoimmune hepatitis, liver disease after liver transplantation, nonalcoholic fatty liver disease, alcoholic hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and congestive hepatopathy etc.
- Without liver tumor and other liver disease besides liver fibrosis
- No history of malignant tumors
- Agree to performe FAPI PET and liver biopsy
Exclusion
- Pregnancy
- With anti-hepatic fibrosis treatment in 6 months
- With contraindications to percutaneous liver biopsy,for such as uncooperative patient, severe coagulopathy, extrahepatic biliary obstruction,etc.
Key Trial Info
Start Date :
December 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05262647
Start Date
December 12 2021
End Date
December 1 2022
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China, 266000